NVCR

16.30

5.73% -0.99

Handel nachbörslich: 16.30

Novocure Ltd (NVCR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt NVCR? Forum Prognose

Schlusskurs vom Vortag:

$17.29

Offen:

$17.2

24-Stunden-Volumen:

1.95M

Relative Volume:

1.19

Marktkapitalisierung:

$1.89B

Einnahmen:

$674.41M

Nettoeinkommen (Verlust:

$-173.05M

KGV:

-10.62

EPS:

-1.5343

Netto-Cashflow:

$-48.07M

1W Leistung:

-5.23%

1M Leistung:

-2.10%

6M Leistung:

+13.59%

1J Leistung:

-11.70%

1-Tages-Spanne:

$16.01

$17.35

1-Wochen-Bereich:

$16.01

$18.08

52-Wochen-Spanne:

$9.82

$18.92

Novocure Ltd Stock (NVCR) Company Profile

Firmenname

Novocure Ltd

Sektor

Healthcare (1096)

Branche

Medical Devices (140)

Telefon

44 (0)15 3475 6700

Adresse

NO. 4 THE FORUM, ST. HELIER

Mitarbeiter

1,605

Twitter

@novocure

Nächster Verdiensttermin

2026-07-23

Neueste SEC-Einreichungen

NVCR's Discussions on Twitter

Compare NVCR vs ABT, SYK, MDT, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NVCR Novocure Ltd	16.30	1.89B	674.41M	-173.05M	-48.07M	-1.5343
ABT Abbott Laboratories	93.93	163.61B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	329.78	126.42B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	83.87	107.36B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	44.77	66.54B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	92.21	53.09B	6.30B	1.07B	1.09B	1.8406

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-25	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-07-08	Eingeleitet	Ladenburg Thalmann	Buy
2024-12-02	Hochstufung	Evercore ISI	In-line → Outperform
2024-10-16	Hochstufung	H.C. Wainwright	Neutral → Buy
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-08-28	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-08-08	Hochstufung	Piper Sandler	Neutral → Overweight
2023-08-04	Eingeleitet	SVB Securities	Outperform
2023-07-31	Hochstufung	Evercore ISI	Underperform → In-line
2023-06-07	Hochstufung	Wedbush	Underperform → Neutral
2023-05-16	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-17	Herabstufung	JP Morgan	Neutral → Underweight
2023-01-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-01-05	Bestätigt	H.C. Wainwright	Buy
2022-11-29	Hochstufung	Wells Fargo	Equal Weight → Overweight
2022-10-24	Herabstufung	Piper Sandler	Overweight → Neutral
2022-07-05	Herabstufung	Evercore ISI	In-line → Underperform
2022-05-16	Eingeleitet	H.C. Wainwright	Buy
2022-02-08	Eingeleitet	Loop Capital	Buy
2022-02-02	Hochstufung	Oppenheimer	Perform → Outperform
2022-01-20	Hochstufung	Truist	Hold → Buy
2022-01-03	Hochstufung	Evercore ISI	Underperform → In-line
2021-07-01	Herabstufung	Mizuho	Buy → Neutral
2021-04-14	Herabstufung	Wedbush	Neutral → Underperform
2021-01-25	Bestätigt	Piper Sandler	Overweight
2020-09-23	Eingeleitet	Northland Capital	Outperform
2020-09-18	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-09-17	Herabstufung	Truist	Buy → Hold
2020-06-01	Fortgesetzt	Oppenheimer	Perform
2020-05-01	Herabstufung	Oppenheimer	Outperform → Perform
2020-04-09	Herabstufung	Evercore ISI	In-line → Underperform
2020-03-05	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-01-02	Herabstufung	Evercore ISI	Outperform → In-line
2019-07-29	Hochstufung	SunTrust	Hold → Buy
2019-07-26	Herabstufung	JP Morgan	Overweight → Neutral
2019-07-26	Herabstufung	Wedbush	Outperform → Neutral
2019-03-20	Eingeleitet	SunTrust	Hold
2018-11-02	Herabstufung	Wells Fargo	Outperform → Market Perform
2018-07-16	Eingeleitet	Evercore ISI	Outperform
2018-04-18	Bestätigt	Mizuho	Buy
2018-02-23	Bestätigt	Mizuho	Buy
2017-05-24	Hochstufung	Wells Fargo	Market Perform → Outperform
2016-07-29	Bestätigt	Wedbush	Outperform
2016-01-19	Eingeleitet	Barclays	Underweight
2015-12-02	Eingeleitet	Deutsche Bank	Hold

Alle ansehen

Novocure Ltd Aktie (NVCR) Neueste Nachrichten

Jul 10, 2026

Does NovoCure’s Shift Into Russell Value Indexes Recast NVCR’s Core Investment Narrative? - simplywall.st

Jul 10, 2026

Jul 09, 2026

Is NovoCure (NVCR) Cheap As TRIDENT Fallout Clouds Its Valuation? - simplywall.st

Jul 05, 2026

Jul 01, 2026

NVCRNovoCure Ltd Volatility & Greeks - Finviz

Jul 01, 2026

NovoCure (NVCR) CHRO acquires 1,905 discounted shares in ESPP purchase - Stock Titan

Jul 01, 2026

NovoCure (NVCR) CEO adds 1,905 shares through 2025 employee share purchase plan - Stock Titan

Jul 01, 2026

NovoCure (NVCR) General Counsel adds 1,299 ESPP shares to holdings - Stock Titan

Jul 01, 2026

NovoCure (NASDAQ: NVCR) director adds shares through 2025 employee stock purchase plan - Stock Titan

Jul 01, 2026

NovoCure's Cancer Treatment Device Option Pax Gets European Approval - Yahoo Finance

Jul 01, 2026

Novocure sets July 23 call for Q2 2026 results before markets open - Stock Titan

Jul 01, 2026

Novocure's Optune Pax Receives EU CE Mark for Pancreatic Cancer Treatment - GuruFocus

Jul 01, 2026

Jun 30, 2026

HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026? - AOL.com

Jun 30, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 30, 2026

Novocure wins CE Mark for Optune Pax pancreatic cancer treatment - grafa.com

Jun 30, 2026

Novocure (NVCR) Gains CE Mark for New Pancreatic Cancer Treatmen - GuruFocus

Jun 30, 2026

Novocure receives CE Mark for pancreatic cancer device in Europe By Investing.com - Investing.com Nigeria

Jun 30, 2026

Novocure’s Optune Pax® Wins CE Mark for Pancreatic Cancer After Phase 3 Success in PANOVA-3 Trial - Minichart

Jun 30, 2026

Novocure receives CE Mark for pancreatic cancer device in Europe - Investing.com

Jun 30, 2026

Optune Pax CE Mark expands Novocure (NASDAQ: NVCR) pancreatic cancer reach - Stock Titan

Jun 30, 2026

Wearable pancreatic cancer device Optune Pax wins CE Mark in Europe - Stock Titan

Jun 30, 2026

Jun 28, 2026

NovoCure (NVCR) Is Up 8.1% After TRIDENT Shows No Survival Gain From Earlier TTFields Start - Sahm

Jun 28, 2026

Jun 27, 2026

NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh - TradingView

Jun 27, 2026

Jun 26, 2026

NovoCure (NVCR) Could Be 42% Undervalued On Mixed TRIDENT Trial Results - simplywall.st

Jun 26, 2026

Jun 25, 2026

NovoCure Ltd. Actuals & Estimates (NASDAQ:NVCR) - TradingView

Jun 25, 2026

NovoCure Ltd. Actuals & Estimates (LSX:A140ML) - TradingView

Jun 25, 2026

NVCR Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 23, 2026

2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Encourages NovoCure Limited (NVCR) Investors to Inquire about Securities Investigation | NDAQ:NVCR | Press Release - Stockhouse

Jun 23, 2026

Jun 22, 2026

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $46 - Moomoo

Jun 22, 2026

NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026? - Yahoo Finance

Jun 22, 2026

Jun 21, 2026

NovoCure StockSunday background on TTFields cancer therapy specialist - AD HOC NEWS

Jun 21, 2026

Jun 20, 2026

NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm - Business Wire

Jun 20, 2026

Jun 19, 2026

NovoCure (NVCR) Is Down 19.7% After TRIDENT Misses Survival Endpoint In Earlier TTFields Use - simplywall.st

Jun 19, 2026

NovoCure (NVCR) Stock Could Be 31.5% Undervalued After TRIDENT Trial Result - Sahm

Jun 19, 2026

Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? - Yahoo Finance

Jun 19, 2026

FreeCast surges premarket; Accenture, Novocure slide By Investing.com - Investing.com Canada

Jun 19, 2026

Jun 18, 2026

Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - Moomoo

Jun 18, 2026

Novocure (NVCR) Experiences Significant Decline in Stock Price - GuruFocus

Jun 18, 2026

NVCR Reiterated by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

Jun 18, 2026

Novocure’s Optune Gio fails to show benefit at earlier stage - Yahoo Finance

Jun 18, 2026

Novocure TRIDENT trial misses primary endpoint - grafa.com

Jun 18, 2026

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $46 - Moomoo

Jun 18, 2026

Novocure (NVCR) Reports TRIDENT Trial Results for Glioblastoma T - GuruFocus

Jun 18, 2026

Novocure Announces Topline Phase 3 TRIDENT Trial Data for TTFields Therapy in Newly Diagnosed Glioblastoma Patients – Minichart - Minichart

Jun 18, 2026

Novocure (NVCR) Faces 20% Drop After Phase 3 Trial Setback - GuruFocus

Jun 18, 2026

Novocure (NVCR) Sees Significant Decline in Stock Price - GuruFocus

Jun 18, 2026

Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks - Benzinga

Jun 18, 2026

Novocure Shares Slide After Phase 3 Glioblastoma Study Falls Short of Survival Goal - Yahoo Finance

Jun 18, 2026

Novocure device fails to improve brain cancer patients’ survival in phase 3 test - Fierce Biotech

Jun 18, 2026